Lifitegrast-d₆  (Synonyms: SAR 1118-d₆; SHP-606-d₆)

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease^[1][2].

621.52

C₂₉H₁₈D₆Cl₂N₂O₇S

2249814-79-5

1025967-78-5

ClC1=C2C(CN(CC2)C(C3=CC=C(C=CO4)C4=C3)=O)=CC(Cl)=C1C(N[C@H](C(O)=O)C([2H])([2H])C5=C([2H])C(S(C)(=O)=O)=C([2H])C([2H])=C5[2H])=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]